No Data
No Data
Why Investors Shouldn't Be Surprised By Sansure Biotech Inc.'s (SHSE:688289) Low P/E
Sansure Biotech Inc. (688289.SH) controlling shareholder and chairman Dai Lizhong proposed enhancing shareholder dividend return.
Sansure Biotech Inc. (688289.SH) announced that the company recently received a document from the actual controller and chairman, Dai Lizhong...
Sansure Biotech Inc. (688289.SH) plans to distribute 2.5 yuan per 10 shares at the semi-annual meeting, with ex-rights and ex-dividends on September 26.
Sanxiong Biotech (688289.SH) announced that the company plans to distribute a cash dividend of CNYX per 10 shares to all shareholders for the first half of 2024...
Sansure Biotech Receives Certification to Register Two Medical Devices
How will Sansure Biotech Inc.'s performance in the first half of the year be impacted by its respiratory products and its second curve strategy? | Earnings conference
①Sansure Biotech Inc. director Dai Lizhong revealed at the earnings conference that the respiratory product revenue for the first half of 2024 is basically on par with the total for the entire previous year. ②The sales of respiratory products exceeded 0.4 billion yuan last year, and the overall revenue for the first half of this year is approximately 0.72 billion yuan. Based on this calculation, the proportion of respiratory product revenue is about 56%.
There Are Reasons To Feel Uneasy About Sansure Biotech's (SHSE:688289) Returns On Capital
No Data
No Data